Updated therapies for the management of Psoriatic Arthritis

Toussi, Atrin; Maverakis, Natalia; Le, Stephanie; Sarkar, Soumajyoti; Raychaudhuri, Smriti K.; Raychaudhuri, S. P.

doi:10.1016/j.clim.2020.108536

Cited by 17 publications

(14 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The parallels we drew between psoriasis and Kawasaki disease blood transcriptional signatures are consistent with the growing body of evidence showing that patients with Kawasaki disease can develop psoriasiform eruptions (44)(45)(46)(47)(48). Among the treatments approved for psoriasis, drugs inhibiting IL17 might be considered good candidates for repurposing in Kawasaki disease (9,49). Independent reports have also associated Th17 responses (defined by IL17 production) with Kawasaki disease (50)(51)(52)(53), and IL17 is a known driver of neutrophil development, recruitment, and activation (54,55).…”

supporting

confidence: 78%

A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis

et al. 2020

View full text Add to dashboard Cite

Transcriptome profiling approaches have been widely used to investigate the mechanisms underlying psoriasis pathogenesis. Most researchers have measured changes in transcript abundance in skin biopsies; relatively few have examined transcriptome changes in the blood. Although less relevant to the study of psoriasis pathogenesis, blood transcriptome profiles can be readily compared across various diseases. Here, we used a pre-established set of 382 transcriptional modules as a common framework to compare changes in blood transcript abundance in two independent public psoriasis datasets. We then compared the resulting “transcriptional fingerprints” to those obtained for a reference set of 16 pathological or physiological states. The perturbations in blood transcript abundance in psoriasis were relatively subtle compared to the changes we observed in other autoimmune and auto-inflammatory diseases. However, we did observe a consistent pattern of changes for a set of modules associated with neutrophil activation and inflammation; interestingly, this pattern resembled that observed in patients with Kawasaki disease. This similarity between the blood-transcriptome signatures in psoriasis and Kawasaki disease suggests that the immune mechanisms driving their pathogenesis might be partially shared.

show abstract

supporting

confidence: 78%

A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal condition characterized by a wide range of symptoms including arthritis, spondylitis, dactylitis, enthesitis, psoriasis and nail disease [1,2]. PsA is also associated with several comorbidities [1][2][3], and can significantly worsen healthrelated quality of life (HR-QOL) [1]. Traditional pharmacological treatment options for PsA include NSAIDs and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) such as methotrexate [1,3].…”

Section: Introductionmentioning

confidence: 99%

“…PsA is also associated with several comorbidities [1][2][3], and can significantly worsen healthrelated quality of life (HR-QOL) [1]. Traditional pharmacological treatment options for PsA include NSAIDs and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) such as methotrexate [1,3]. Over recent decades, the development of biological DMARDs (bDMARDs) has considerably changed the PsA treatment landscape [1].…”

Section: Introductionmentioning

confidence: 99%

Secukinumab: A Review in Psoriatic Arthritis

Blair

2021

Drugs

View full text Add to dashboard Cite

Secukinumab (Cosentyx ® ) is a fully human monoclonal antibody that selectively targets interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA). Administered subcutaneously, the first-in-class anti-IL-17 agent is approved in numerous countries worldwide for the treatment of adults with active PsA. In the phase III FUTURE trials, secukinumab 150 or 300 mg improved the clinical signs and symptoms of PsA versus placebo in patients with active disease despite previous treatment with NSAIDs, biological disease-modifying anti-rheumatic drugs (bDMARDs) and/or tumour necrosis factor inhibitors (TNFi). The benefits of secukinumab were seen regardless of whether or not patients had received previous TNFi therapy, and were maintained during longer term (up to 5 years) treatment. In FUTURE 1 and 5, secukinumab inhibited structural joint damage and was associated with sustained low rates of radiographic progression through 1-3 years of treatment. Treatment with secukinumab improved physical function and health-related quality of life (HR-QOL) and was generally well tolerated, both in the short-and longer-term. In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain. In conclusion, secukinumab is effective across all key PsA domains and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with active PsA.

show abstract

“…2020; Toussi et al. 2020; Van den Bosch and Coates 2018). For many people with PsA, these pharmaceuticals will more or less work, tempering disease activity enough so that they can function a majority of the time.…”

Section: Chronic Pain and Sufferingmentioning

confidence: 99%

Chronic Pain and the Arcs of Suffering and Well‐Being: A Systems Model of/for Living with Psoriatic Arthritis

Singstock¹,

Hay²,

Hyland³

2022

Ethos

View full text Add to dashboard Cite

Chronic pain is a phenomenon in which the biological sensations of pain interact synergistically with an individual's cultural world. Considerable anthropological work has been done on the senses and on the anthropology of chronic pain. Less attention has been given to the sensations of chronic pain, how they can escalate to suffering, and how they may be managed in daily life to enable well-being. To develop an integrated understanding of chronic pain processes, we worked as a collaborative research team that included a patient coauthor. Together we synthesized a model that outlines the biological pathways of pain while taking into account the cultural factors that can magnify pain into arcs of suffering or temper pain toward arcs of well-being.Drawing on scholarly literature, long-term ethnographic research, and personal experience with autoimmune disease, we propose a dynamic model of the moment-to-moment arcs that maintain, magnify, or temper pain.[pain, suffering, well-being, autoimmune disease, and systems model] Spanish abstract: El dolor crónico es un fenómeno en el que las sensaciones biológicas del dolor son sinérgicamente interactivas con el mundo cultural del individuo. Ha sido mucho trabajo antropológico en los sentidos y la antropología del dolor crónico. Menos atención ha prestado a las sensaciones del dolor crónico, su crecimiento a sufrimiento y cómo estas sensaciones pueden ser manejadas en la vida cotidiana para facilitar el bienestar. El desarrollo de un entendimiento integrativo de los procesos del dolor crónico exigió un equipo de investigación integrativo y colaborativo, lo que incluyó un paciente como coautor. Juntos, resumimos un modelo que esboza las vías biológicas del dolor mientras abarcando los factores culturales que amplifican el dolor a ciclos de retroalimentación de sufrimiento o, alternativamente, templan el dolor a ciclos de retroalimentación de bienestar. Con el apoyo de literatura académica, investigaciones en etnografía prolongadas y experiencia personal de enfermedades autoinmunitarias, propongamos un modelo dinámico de ciclos de retroalimentación instantáneos que mantienen, magnifican otemplan el dolor. [dolor, sufrimiento, bienestar, enfermedad autoinmune, modelo sistemático] On good days, Kerby's pain and related physical limitations are manageable. On bad days, getting out of bed and putting on clothes is profoundly difficult, if not impossible. For Kerby and many others with autoimmune-related chronic pain, pain itself is an unreliable warning sign, like a smoke alarm that is always ringing. Kerby has learned to recognize the contours of his pain sensations as a more reliable indicator of his current condition, and the sensations he will likely feel in the immediate future. For Kerby, pain has been a regular companion since his childhood in the 1960s. He has learned to mitigate the pain through practices including

show abstract

Updated therapies for the management of Psoriatic Arthritis

Cited by 17 publications

References 69 publications

A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis

A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis

Secukinumab: A Review in Psoriatic Arthritis

Chronic Pain and the Arcs of Suffering and Well‐Being: A Systems Model of/for Living with Psoriatic Arthritis

Contact Info

Product

Resources

About